http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 15:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Press+Releases/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html <p align="justify">BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a <strong>Health Canada Medical Device Licence</strong> authorizing the commercialization of its <strong>CARA System</strong> in Canada.</p> <p align="justify">CARA System technology integrates AI-powered analysis modules within a single clinician-controlled workflow:</p> <ul><li><strong>CARA-AMDdetect</strong> – Age-related macular degeneration detection</li><li><strong>CARA-DR</strong> – Diabetic retinopathy detection</li><li><strong>CARA-MVA</strong> – Retinal microvascular analysis</li><li><strong>CARA-Enhancement</strong> – Advanced retinal image enhancement</li><li><strong>CARA-CWS</strong> - http://www.streetinsider.com/Globe+Newswire/DIAGNOS+Receives+Health+Canada+Medical+Device+Licence+for+CARA+System%2C+Bringing+AI-Assisted+Retinal+Image+Analysis+to+Canadian+Optometrists/26819222.html Mon, 27 Jul 2026 15:20:00 -0400 4D4A A.06822034 A.17150087 ADK DGNOF O.02535360 O.20026344 O.34929518 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Press+Releases/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813 http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html <p align="justify">BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (<em>AI</em>) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.</p> <p align="justify">All other provisions of the Warrants, such as the exercise http://www.streetinsider.com/Globe+Newswire/DIAGNOS+to+Extend+the+Exercise+Period+of+Stock+Warrants/26740872.html Tue, 07 Jul 2026 12:38:00 -0400 4D4A A.36078215 ADK DGNOF O.02535360 O.02555813